Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: Provided herein are macrolide compounds of Formula (I) and (I-N) for the treatment of infectious diseases and inflammatory conditions. The 14-membered ketolides and 14-, 15-, and 16-membered azaketolides described herein comprise modified sugars which are desosamine or mycaminose analogs. Pharmaceutical compositions and methods of treating infection diseases and inflammatory conditions using the inventive macrolides are also provided. This disclosure additionally provides methods of preparing the macrolides by the coupling of an eastern and western half.

Abstract: Provided herein are purified hemicellulose compositions, sweetener compositions including purified hemicellulose compositions, as well as methods for making the same. Also provided are uses of the compositions.

Abstract: Molded articles are disclosed herein, the molded article comprising a polysaccharide, wherein the polysaccharide comprises i) poly alpha-1,3-glucan; ii) poly alpha-1,3-1,6-glucan; iii) a graft copolymer that comprises (A) a backbone comprising dextran with a weight-average molecular weight (Mw) of at least about 100000 Daltons, and (B) poly alpha-1,3-glucan side chains comprising at least about 95% alpha-1,3-glucosidic linkages; or iv) a composition comprising a poly alpha-1,3-glucan ester compound as disclosed herein. Optionally, the molded articles can further comprise a plasticizer and/or starch. The molded articles can be useful as a container, a handle, packaging, a tray, a bottle, a cup, a sheet, a disposable food packaging item, an automotive part, a casing for an electronic device, or a toy.

Abstract: It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.

Abstract: In one aspect, the disclosure relates to a facile strategy to introduce electron-deficient aryl sulfate diesters to silylated hydroxyl groups of carbohydrates and amino acids, among other substrates, wherein selective hydrolysis and the removal of an electron-deficient aromatic group allows for the efficient generation of sulfated carbohydrates, peptides, and other compounds. The incorporation of electron-deficient aryl sulfate diesters in the early stage of the synthesis of glycans, peptides, and the like, disclosed herein avoids time-consuming protecting group manipulations, simplifies the purification of sulfated products, and improves the overall yield and efficiency. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: A method of treating a subject afflicted with oxidative stress due to radiation exposure has the steps of preparing glucosidic astaxanthin by reacting astaxanthin with a monosaccharide, and administering a therapeutic amount of the glucosidic astaxanthin to the subject in need of such treatment. The astaxanthin is reacted with the monosaccharide at a microwave frequency of between 1 and 100 GHz for at least one second and no more than 25 seconds. The glucosidic astaxanthin can be added to a carrier material.

Abstract: A compound includes a polysaccharide moiety and one or more chelating agents. The one or more chelating agents are covalently bonded to the polysaccharide moiety. The polysaccharide moiety can include a glycosaminoglycan moiety, such as a hyaluronic acid polymer or a sulfated glycosaminoglycan moiety. The compound can be used to treat or prevent a disease or disorder in a patient with a metal implant. The compound reduces a concentration of metal particulates or metal ions in the subject.

Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Abstract: Broth compositions prepared from poultry are disclosed. Selected poultry raw materials are processed to obtain a broth having high protein content. Certain specific amino acids and proteins are present at relatively higher concentration as compared to home-made broth. The disclosed broth compositions are effective in preventing and/or treating metabolic syndrome and may also provide other nutritional and health benefits.

Abstract: A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).

Abstract: A process for preparing a recycle cellulose ester and a recycle cellulose ester composition and articles made with such recycle cellulose esters comprising at least one cellulose ester having at least one substituent on an anhydroglucose unit (AU) derived from recycled plastic content syngas are provided. The recycled plastic content syngas can be obtained by gasifying feedstocks containing a solid fossil fuel such as coal, a plastic, and water. The plastic can be post-consumer or postindustrial plastic.

Abstract: The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is ?90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Abstract: The present invention provides a process for the preparation of essential oil modified nanocellulose and applications thereof. The invention further provides a process wherein the essential oil is covalently bonded with the nanocellulose such that the essential oil does not leach out. The edible coatings comprising the developed essential oil modified nanocellulose thus exhibit a prolonged antimicrobial effect.

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.